NDC 50222-346 – Adbry
Tralokinumab 150 mg/mL · Injection, Solution · Subcutaneous
Product NDC50222-346
Product details
- Brand name
- Adbry
- Generic name
- Tralokinumab-ldrm
- Labeler
- LEO Pharma Inc.
- Dosage form
- Injection, Solution
- Route
- Subcutaneous
- Marketing category
- BLA · BLA761180
- Marketed since
- January 2, 2022
- Listing expires
- December 31, 2026
- Pharmacologic class
- Interleukin-13 Antagonist
Active ingredients
- Tralokinumab 150 mg/mL
Package NDC codes (3)
| Package NDC | Description | Since |
|---|---|---|
| 50222-346-02 | 2 SYRINGE, GLASS in 1 CARTON (50222-346-02) / 1 mL in 1 SYRINGE, GLASS (50222-346-01) | Jan 2, 2022 |
| 50222-346-04 | 2 CARTON in 1 CARTON (50222-346-04) / 2 SYRINGE, GLASS in 1 CARTON (50222-346-22) / 1 mL in 1 SYRINGE, GLASS (50222-346-01) | Jan 2, 2022 |
| 50222-346-92 | 2 SYRINGE, GLASS in 1 CARTON (50222-346-92) / 1 mL in 1 SYRINGE, GLASS (50222-346-91) | Jan 2, 2022 |
Recalls mentioning this NDC
- D-0339-2026 Mar 4, 2026 · Class II
Lack of Assurance of Sterility: due to the presence of particulate matter in one unit from the lot, which lab tests have identified as wool fiber.
Other Adbry products
- 50222-350 Tralokinumab 300 mg/2mL · Injection, Solution · LEO Pharma Inc.